Metformin for Heart Failure With Preserved Ejection Fraction (HFpEF)

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Heart Failure With Preserved Ejection Fraction (HFpEF)+1 More
Metformin - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study the effects of metformin on heart failure patients with preserved ejection fraction.

Eligible Conditions
  • Heart Failure With Preserved Ejection Fraction (HFpEF)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Heart Failure With Preserved Ejection Fraction (HFpEF)

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Week 20

Week 20
6-minute walk distance (6MWD)
C-reactive protein
Fecal Mucin
Interleukin-6
Cardiomyopathies
Lipopolysaccharide binding protein (LBP)
Peak VO2
Short Physical Performance Battery (SPPB)
Tumor necrosis factor-alpha

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Heart Failure With Preserved Ejection Fraction (HFpEF)

Trial Design

2 Treatment Groups

Metformin
1 of 2
Placebo
1 of 2
Active Control
Non-Treatment Group

80 Total Participants · 2 Treatment Groups

Primary Treatment: Metformin · Has Placebo Group · Phase 2

Metformin
Drug
ActiveComparator Group · 1 Intervention: Metformin · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: week 20

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,113 Previous Clinical Trials
1,129,589 Total Patients Enrolled
2 Trials studying Heart Failure With Preserved Ejection Fraction (HFpEF)
880 Patients Enrolled for Heart Failure With Preserved Ejection Fraction (HFpEF)
University of South FloridaOTHER
367 Previous Clinical Trials
100,074 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,380 Previous Clinical Trials
3,446,676 Total Patients Enrolled
5 Trials studying Heart Failure With Preserved Ejection Fraction (HFpEF)
985 Patients Enrolled for Heart Failure With Preserved Ejection Fraction (HFpEF)
Dalane W. Kitzman, MDPrincipal InvestigatorWake Forest University Health Sciences
2 Previous Clinical Trials
429 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
This study is evaluating whether a new definition of heart failure with preserved ejection fraction (HFpEF) will improve the ability to identify people with heart failure who are at high risk of dying.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 17th, 2021

Last Reviewed: October 9th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.